Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

NCT02269813 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.

NCT NCT02269813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02269813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)
Lead sponsor
Women's Cancer Study Group GmbH
Phase
Observational
Overall status
Completed
Start date
April 1, 2015
Completion date
September 30, 2016
Enrollment
452 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer